In Denmark, a 2022 study revealed that GLP-1s significantly reduced alcohol consumption in thousands of adults within the first three months of starting the drug compared with another medication
Disclosures: Arunkumar Krishnan: Nothing to Disclose, Diptasree Mukherjee: Nothing to Disclose, Carolin Schneider: Nothing to Disclose, Tinsay Woreta: Nothing to Disclose, Saleh Alqahtani: Nothing to Disclose 1624 SAROGLITAZAR IS MORE EFFECTIVE THAN SIMVASTATIN IN REDUCING STEATOSIS IN PATIENTS WITH MET-ALD Anand Kulkarni 1 Ramyasri Ramagundam 2 Zaid Mohammed Gangdany 2 Mithun Sharma 3 Manasa Alla 2 Shantan Venishetty 2 Sowmya T R 2 Padaki Nagaraja Rao 2 Nageshwar Reddy 2 , 1 Asian Institute of Gastroenterology, 2 AIG Hospitals, 3 ASIAN INSTITUTE OF GASTROENTROLOGY PVT LTD Background: MetALD is the new term proposed to identify patients with steatotic liver disease, who concomitantly consume alcohol (210-420 g/week)
Your home refrigerator should maintain this range consistentlycheck it with a thermometer if you're uncertain
The influence of race and ethnicity on the biology of cancer
The degree of colocalization of GLP-1R and -SMA was calculated using ImageJ (NIH)
)
